Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

848 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, Attar E, Hobbs GS, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger DR, Iafrate A, Graubert TA, Stone RM, Fathi AT. Brunner AM, et al. Among authors: connolly c. Cancer. 2019 Feb 15;125(4):541-549. doi: 10.1002/cncr.31729. Epub 2018 Nov 13. Cancer. 2019. PMID: 30422308 Free article.
Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.
Fathi AT, DeAngelo DJ, Stevenson KE, Kolitz JE, Asch JD, Amrein PC, Attar EC, Steensma DP, Wadleigh M, Foster J, Connolly C, Galinsky I, Devoe CE, Stone RM, Neuberg DS, Ballen KK. Fathi AT, et al. Among authors: connolly c. Cancer. 2016 Aug 1;122(15):2379-88. doi: 10.1002/cncr.30037. Epub 2016 May 12. Cancer. 2016. PMID: 27171984 Free article. Clinical Trial.
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance NM, Manning AL, Sadrzadeh H, Ballen KK, Attar EC, Graubert TA, Hobbs G, Joseph C, Perry AM, Burke M, Silver R, Foster J, Bergeron M, Ramos AY, Som TT, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Chen YB. Fathi AT, et al. Among authors: connolly c. Haematologica. 2017 Apr;102(4):719-727. doi: 10.3324/haematol.2016.158394. Epub 2016 Dec 29. Haematologica. 2017. PMID: 28034990 Free PMC article. Clinical Trial.
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ. Fathi AT, et al. Among authors: connolly c. Cancer. 2018 Jan 15;124(2):306-314. doi: 10.1002/cncr.31038. Epub 2017 Sep 28. Cancer. 2018. PMID: 28960265 Free PMC article.
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.
Brunner AM, Blonquist TM, DeAngelo DJ, McMasters M, Fell G, Hermance NM, Winer ES, Lindsley RC, Hobbs GS, Amrein PC, Hock HR, Steensma DP, Garcia JS, Luskin MR, Stone RM, Ballen KK, Rosenblatt J, Avigan D, Nahas MR, Mendez LM, McAfee SL, Moran JA, Bergeron M, Foster J, Bertoli C, Manning AL, McGregor KL, Fishman KM, Kuo FC, Baltay MT, Macrae M, Burke M, Behnan T, Wey MC, Som TT, Ramos AY, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg DS, Chen YB, Graubert TA, Fathi AT. Brunner AM, et al. Among authors: connolly c. Lancet Haematol. 2020 Feb;7(2):e122-e133. doi: 10.1016/S2352-3026(19)30203-0. Epub 2019 Dec 11. Lancet Haematol. 2020. PMID: 31837959 Free PMC article. Clinical Trial.
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R, Blonquist TM, Emadi A, Hasserjian RP, Burke M, Lescinskas C, Neuberg DS, Brunner AM, Hobbs G, Hock H, McAfee SL, Chen YB, Attar E, Graubert TA, Bertoli C, Moran JA, Bergeron MK, Foster JE, Ramos AY, Som TT, Vartanian MK, Story JL, McGregor K, Macrae M, Behnan T, Wey MC, Rae J, Preffer FI, Lesho P, Duong VH, Mann ML, Ballen KK, Connolly C, Amrein PC, Fathi AT. Narayan R, et al. Among authors: connolly c. Cancer. 2020 Mar 15;126(6):1264-1273. doi: 10.1002/cncr.32657. Epub 2019 Dec 20. Cancer. 2020. PMID: 31860140 Free article. Clinical Trial.
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, Connolly C, Ballen KK, Cutler CS, Dey BR, El-Jawahri A, Nikiforow S, McAfee SL, Koreth J, Deangelo DJ, Alyea EP, Antin JH, Spitzer TR, Stone RM, Soiffer RJ, Chen YB. Brunner AM, et al. Among authors: connolly c. Br J Haematol. 2016 Nov;175(3):496-504. doi: 10.1111/bjh.14260. Epub 2016 Jul 19. Br J Haematol. 2016. PMID: 27434660 Free PMC article.
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
Chen YB, Li S, Lane AA, Connolly C, Del Rio C, Valles B, Curtis M, Ballen K, Cutler C, Dey BR, El-Jawahri A, Fathi AT, Ho VT, Joyce A, McAfee S, Rudek M, Rajkhowa T, Verselis S, Antin JH, Spitzer TR, Levis M, Soiffer R. Chen YB, et al. Among authors: connolly c. Biol Blood Marrow Transplant. 2014 Dec;20(12):2042-8. doi: 10.1016/j.bbmt.2014.09.007. Epub 2014 Sep 17. Biol Blood Marrow Transplant. 2014. PMID: 25239228 Free PMC article. Clinical Trial.
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.
Amrein P, Ballen K, Stevenson K, Brunner A, Hobbs G, Hock H, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, McGreggor K, Macrea M, Burke M, Behnam T, Som T, Ramos A, Vartanian M, Lombardi Story J, Connolly C, Blonquist T, Neuberg D, Fathi A. Amrein P, et al. Among authors: connolly c. Leuk Lymphoma. 2022 Jun;63(6):1428-1435. doi: 10.1080/10428194.2021.2018582. Epub 2022 Jan 25. Leuk Lymphoma. 2022. PMID: 35075985
Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.
Kasbekar M, Nardi V, Dal Cin P, Brunner AM, Burke M, Chen YB, Connolly C, Fathi AT, Foster J, Macrae M, McAfee SL, McGregor K, Narayan R, Ramos AY, Som TT, Vartanian M, Friedman RS, Benhadji KA, Hobbs GS. Kasbekar M, et al. Among authors: connolly c. Blood Adv. 2020 Jul 14;4(13):3136-3140. doi: 10.1182/bloodadvances.2020002308. Blood Adv. 2020. PMID: 32649766 Free PMC article.
848 results